VIVIO, a Public Benefit Corporation

WEBINAR Nov 20th • 12PM EST • 9AM PST  Open Markets, Better Outcomes, Lower Costs: A Discussion with Mark Cuban and Pramod John on Healthcare Innovation     PBMs have long claimed to reduce drug costs and enhance healthcare value, but their complex business practices have instead increased medication costs through hidden fees, rebate schemes, and anti-competitive pricing. Operating as expensive intermediaries, they have effectively extracted billions from the healthcare system while failing to deliver on their promise of cost control and value addition to patients and employers.    REGISTER NOW: https://lnkd.in/gV456mZ5     The success of open markets in reducing costs across industries like retail (Amazon), transportation (Uber, Lyft, Tesla), and travel suggests a similar approach could transform healthcare. While transparent PBMs represent a step in the right direction, there's potential for even more significant improvements through market-based solutions that could help achieve better outcomes at lower costs.     Mark Cuban, cofounder of Mark Cuban Cost Plus Drug Company, PBC, believes his transparent pricing model could be his most impactful venture yet. Pramod John, CEO of VIVIO, a Public Benefit Corporation, will introduce VIVIO's PrecisionCare One platform which offers an open market, data-driven alternative to the PBM model.    Join us for a no-holds-barred discussion where Mark and Pramod explore how open markets are revolutionizing healthcare purchasing.     Discover how self-insured companies can fulfill their fiduciary duties while enhancing corporate wellness programs, improving benefits, reducing costs, and delivering better health outcomes for their employees. Webinar Discussion Points:  - Right drug, right person, right price, the right outcome – the core mission  - The power of open markets  - Proof in action: Cost Plus Drugs transformed generics pricing, VIVIO revolutionized specialty drug management  - Why PBM contract gibberish like rebate and discount guarantees leads to higher costs  - Current PBM practices create legal risks for employers and their fiduciary duties  - Replacing PBMs with transparent, open market solutions is possible today    Can't make it live? Register anyway, and we’ll send you the webinar recording.    REGISTER NOW: https://lnkd.in/gV456mZ5    Who Should Join?  This webinar is designed for employers, benefits consultants, employee benefits professionals, the media, and anyone interested in understanding how open markets can transform healthcare.    Registration Bonus: Registrants will be invited to join a special LinkedIn Live follow-up event on November 21 at 1pm EST, 10am PST.    #HealthcareInnovation #OpenMarkets #PBMReform #DrugPricing #EmployeeBenefits #MarkCuban #VIVIO

WEBINAR Nov 20th • 12PM EST • 9AM PST Open Markets, Better Outcomes, Lower Costs: A Discussion with Mark Cuban on Healthcare Innovation PBMs have long claimed to reduce drug costs and enhance healthcare value, but their complex business practices have instead increased medication costs through hidden fees, rebate schemes, and anti-competitive pricing. Operating as expensive intermediaries, they have effectively extracted billions from the healthcare system while failing to deliver on their promise of cost control and value addition to patients and employers.   The success of open markets in reducing costs across industries like retail (Amazon), transportation (Uber, Lyft, Tesla), and travel suggests a similar approach could transform healthcare. While transparent PBMs represent a step in the right direction, there's potential for even more significant improvements through market-based solutions that could help achieve better outcomes at lower costs.   Mark Cuban, cofounder of Mark Cuban Cost Plus Drug Company, PBC, believes his transparent pricing model could be his most impactful venture yet. Pramod John, CEO of VIVIO, a Public Benefit Corporation, will introduce VIVIO's PrecisionCare One platform which offers an open market, data-driven alternative to the PBM model. Join us for a no-holds-barred discussion where Mark and Pramod explore how open market solutions are revolutionizing healthcare purchasing. Discover how self-insured companies can fulfill their fiduciary duties while enhancing corporate wellness programs, improving benefits, reducing costs, and delivering better health outcomes for their employees. Register at: https://lnkd.in/gZWin4sN #OpenMarketSolutions #HealthcareInnovation #MarkCuban #PramodJohn #EmployeeBenefits

Last week, our CEO, Pramod John, joined a panel of industry leaders at The Healthcare Innovation Company (thINc) conference. They explored the downfalls of traditional PBM models and discussed how we can make way for more innovative solutions. It was a great discussion filled with laughs, honesty and thought-provoking questions. Thank you to everyone who attended! #PharmacyBenefitManagers #VIVIO #Thinc360 #HealthcareInnovation

Don't forget to join us this morning at 11:00am in meeting room 12/13/14! Our CEO, Pramod John, joins other experts in the industry to explore alternative approaches to the PBM model and discuss how innovative solutions can offer more flexibility in personalizing drug therapies and cost transparency. See you there! #thinc360 #healthcareinnovation #thinc360conference #vivio

Don't miss this exciting conversation on pharmacy benefits strategies at the upcoming The Healthcare Innovation Company (thINc) conference. Our CEO, Pramod John, joins fellow pharmacy benefits experts to discuss the implications of the conventional PBM landscape and how employers are embracing new models in the industry. Looking forward to seeing everyone in DC! #THINC360 #THINC3602024 #VIVIO #PharmacyBenefits

Any final thoughts for our members? - Mark Wilson, HR Policy Association Short video: (51 seconds) There’s only one way to fix this problem …  you have to be willing to change the model. We can’t keep doing what we’re doing. - Pramod John, VIVIO, a Public Benefit Corporation #LowerCosts, #SpecialtyDrugs, #NoPBM, #BetterOutcomes, #BetterHealth

A study conducted by The Johns Hopkins University found that in 80% of cases, it was cheaper for patients in their deductible phase to pay cash for a drug than to use their insurance. In the latest episode of The H.I.T. Podcast, our CEO, Pramod John, sat down with Tobias Kennedy to discuss why this trend exists and how the only way to avoid overpaying for specialty drugs is to think outside of the traditional PBM model. The two dive into the J&J Fiduciary lawsuit, the necessity of an open-market approach in healthcare, and how Mark Cuban and Mark Cuban Cost Plus Drug Company, PBC are transforming the industry through transparency. Tune in to the full episode at the link below! https://lnkd.in/gyjP2Rce